NEWSROOM
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024 Achieves second consecutive quarter of positive net income with $6.3 million Generated Adjusted Q2 2024 EBITDA of $10.0 million Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT POMPANO...
SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products
MIAMI, FL, August 12, 2024 – SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 97 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today reported its financial and operational results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Achievements Generated...
AB INTL GROUP Reports of Financial Results for period ending May 31, 2024 and achieved Net Profitability
NEW YORK, August 12, 2024 -- AB International Group Corp. (OTC: ABQQ), an intellectual property (IP) and movie investment and licensing firm, announces its financial results for the period ended May 31, 2024. The financial results have been filed in a 10-Q with the U.S. Securities and Exchange Commission (the "SEC"). Key Financial Highlights: Revenues for the three months ended May 31, 2024, increased 22% to $698,311, as compared to $573,389 for the three months ended May 31, 2023. Net income...
StemSation International Provides Corporate Updates
StemSation International is providing updates on corporate planning and direction as they execute on an expanded business model Plantation, Florida, August 12, 2024 – StemSation International (OTC: STSN), a South-Florida based company that has licensed technology for the production and distribution of flavored, canned oxygen products is announcing new business initiatives for the upcoming months. "We announced last year that we had streamlined our current business and would be seeking further...
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
Melanocortin receptors on neurons in the brain control feeding and weight loss Patented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, NY, August 09, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate...
Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results
Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssureTM, which is our research-use-only assay that can detect...
Premier Graphene President Pedro Mendez Meets with Global Leader in Sustainable Construction
Premier’s Graphene Suspensions Receiving Interest from one of the World’s Largest Materials Handling Companies EL CENTRO, California, August 8, 2024 – Premier Graphene, Inc. (OTC PINK: BIEI) announced today that one of the world’s largest materials handling company invited Premier Graphene to permit them to test and separately confirm HGI's proprietary hemp-based graphene formulation in concrete with respect to which it has a distribution license in the United States. Impressed with the...
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...
BLAQclouds, Inc. Announces Intent to Acquire ZEUS Blockchain Partners
Las Vegas, NV, August 07, 2024 — BLAQclouds, Inc. (OTC: BCDS) is pleased to announce the intent to acquire the equity of ZEUS Blockchain Partners, Inc. through a SAFE Agreement. As part of this process BLAQclouds, Inc. now has a 90-day exclusive period to complete the transaction. ZEUS Blockchain Partners, Inc. has developed https://zeuschainscan.io/, a Layer 1 Ethereum Virtual Machine (EVM) chain, premiered with the ZEUS Token. The ZEUS Token has also been integrated as the settlement token...